Dyson, Jessica K.
Hirschfield, Gideon M.
Adams, David H.
Beuers, Ulrich
Mann, Derek A.
Lindor, Keith D.
Jones, David E. J.
Article History
First Online: 3 February 2015
Competing interests
: G.M.H. is an investigator and/or consultant for Biotie Therapies, Bristol–Myers Squibb, Falk Pharma, FF Pharma, Gilead, GlaxoSmithKline, Intercept, Johnson & Johnson, NGM Biopharmaceuticals; he is a co-investigator for UK PBC, supported by a stratified medicine award from the UK Medical Research Council. U.H.B has consultant agreements via the University of Amsterdam with Intercept and Novartis, and receives lectures fees from the Falk Foundation. D.A.M. is a consultant and collaborator with GlaxoSmithKline, Medimmune, Novartis, UCB. K.D.L. is an unpaid member of the advisory board for Intercept and Lumena and a paid consultant for Abbvie and Gilead. D.E.J.J. receives UK PBC research and trial funding from GlaxoSmithKline, Intercept and Lumena, and acts as a consultant via Newcastle University for Intercept, Johnson & Johnson and Novartis. The other authors declare no competing interests.